The Defense Health Agency awarded the University of Wisconsin – Madison $560,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research into exploiting epigenetic dysregulation for sarcoma treatment. The project will run through October 31, 2029, with work performed in Madison, Wisconsin. This is a Project Grant assistance type supporting basic and applied biomedical research aimed at transforming health care for Service Members and the American public through innovative medical solutions.